Di Bona D, et al. - Researchers systematically reviewed randomized studies comparing allergen immunotherapy (AIT) to placebo/pharmacotherapy for the treatment of respiratory allergies to molds, with a focus on safety and reduction of symptoms (Symptom Score, SS) and medication use (Medication Score, MS) in patients treated with AIT vs controls. Excluded studies included those not reporting on the outcome of interest or without a control population. Mold AIT was found to be efficacious for the treatment of respiratory allergies, as indicated by low strength evidence. Studies with a longer follow-up and low-risk of bias demonstrated the highest benefit of AIT vs pharmacotherapy/placebo. Of participants who received sublingual immunotherapy and those treated with subcutaneous immunotherapy, generalised adverse reactions were reported in 12.5% and 37.2%, respectively.